Alharbi, F F
Souverein, P C
de Groot, M C
Maitland-van der Zee, A H
de Boer, A
Klungel, O H
Article History
Received: 30 June 2016
Revised: 17 December 2016
Accepted: 3 January 2017
First Online: 23 March 2017
Competing interests
: OHK and MCdG had received unrestricted funding for pharmacoepidemiological research from the Dutch private-public funded Top Institute Pharma (TI Pharma Grant T6.101 Mondriaan) until 2012 and from the PROTECT project that has received support from the Innovative Medicine Initiative Joint Undertaking (ExternalRef removed) under grant agreement no 115004, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contribution. In the context of the IMI Joint Undertaking, the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, also received a direct financial contribution from Pfizer. The remaining authors declare no other conflicts.